Novartis India lost 2.82% to Rs 641.95 at 09:16 IST on BSE after net profit dropped 63.14% to Rs 7.03 crore on 32.98% decrease in net sales to Rs 114.81 crore in Q1 June 2017 over Q1 June 2016.
The result was announced after market hours yesterday, 27 July 2017.Meanwhile, the S&P BSE Sensex was down 134.80 points, 0.42% at 32,248.50. The S&P BSE Small-Cap index was down 37.60 points, or 0.23% at 15,977.87.
On the BSE, 839 shares were traded on the counter so far as against the average daily volumes of 9,774 shares in the past one quarter. The stock had hit a high of Rs 654 and a low of Rs 641.10 so far during the day. The stock had hit a 52-week high of Rs 785 on 18 April 2017 and hit a 52-week low of Rs 615 on 25 May 2017.
The small-cap company has equity capital of Rs 14.07 crore. Face value per share is Rs 5.
Novartis India has core businesses in pharmaceuticals, vaccines, consumer health, generics, and eye care. Novartis AG holds 73.4% stake in Novartis India (as per the shareholding pattern as on 30 June 2017).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
